Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial

被引:18
|
作者
Gontijo-Amaral, Clesio [1 ]
Guimaraes, Elizabet V. [1 ]
Camargos, Paulo [1 ,2 ]
机构
[1] Fed Univ Minas Gerais UFMG, Fac Med, Dept Pediat, Diagnost Support Act & Res Ctr NUPAD, Belo Horizonte, MG, Brazil
[2] Univ Fed Sao Joao del Rei, Postgrad Program Hlth Sci, Hlth Sci Ctr, Divinopolis, Brazil
来源
关键词
RESPIRATORY MUSCLE STRENGTH; ASTHMATIC-CHILDREN; DIETARY MAGNESIUM; LONG-TERM; HYPOMAGNESEMIA; INFLAMMATION; METAANALYSIS; PRESSURES; PANCREAS; DISEASE;
D O I
10.3945/ajcn.112.034207
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Magnesium is one of the most important minerals in the body. Although some studies reported that patients with cystic fibrosis (CF) lack magnesium, no international study has assessed the importance of oral magnesium supplementation in CF patients. Objective: We prospectively investigated the long-term effect of oral magnesium supplementation on respiratory muscle strength by using manuvacuometry and the Shwachman-Kulczycki (SK) score among children and adolescents with CF. Design: This double-blind, randomized, placebo-controlled crossover study included 44 CF patients (aged 7-19 y; 20 males) who were randomly assigned to receive magnesium (n = 22; 300 mg/d) or placebo (n = 22) for 8 wk with a 4-wk washout period between trials. All patients were undergoing conventional treatment of CF. The experimental protocol included clinical evaluation, assessment of urinary concentration of magnesium, and manuvacuometric measurements [maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP)]. MIP was the primary outcome. Results: Urinary magnesium increased after the administration of magnesium (change: 36.38 mg/d after magnesium compared with 0.72 mg/d after placebo; P < 0.001). Moreover, MIP and MEP significantly improved only after magnesium administration (change in MIP: 11% predicted after magnesium compared with 0.5% predicted after placebo; change in MEP: 11.9% predicted after magnesium compared with 0.8% predicted after placebo; P < 0.001 for both). Magnesium administration had a beneficial effect on clinical variables assessed by the SK score (change: 4.48 points after magnesium compared with -1.30 points after placebo; P < 0.001). Conclusion: Oral magnesium supplementation helped improve both the SK score and respiratory muscle strength in pediatric patients with CF. This trial was registered at www.ufmg.br.bioetica/coep as CAAEO 559.0.203.000-07. Am J Clin Nun 2012;96:50-6.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [1] Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial
    C Gontijo-Amaral
    M A G O Ribeiro
    L S C Gontijo
    A Condino-Neto
    J D Ribeiro
    [J]. European Journal of Clinical Nutrition, 2007, 61 : 54 - 60
  • [2] Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial
    Gontijo-Amaral, C.
    Ribeiro, M. A. G. O.
    Gontijo, L. S. C.
    Condino-Neto, A.
    Ribeiro, J. D.
    [J]. EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2007, 61 (01) : 54 - 60
  • [3] Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial
    Rodriguez-Moran, Martha
    Simental-Mendia, Luis E.
    Gamboa-Gomez, Claudia, I
    Guerrero-Romero, Fernando
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2018, 25 (03) : 261 - 266
  • [4] Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial
    Bozic, Molly
    Goss, Christopher H.
    Tirouvanziam, Rabindra M.
    Baines, Arthur
    Kloster, Margaret
    Antoine, Liebe
    Borowitz, Drucy
    Schwarzenberg, Sarah Jane
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 71 (06): : 771 - 777
  • [5] Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial
    Guerrero-Romero, F.
    Simental-Mendia, L. E.
    Hernandez-Ronquillo, G.
    Rodriguez-Moran, M.
    [J]. DIABETES & METABOLISM, 2015, 41 (03) : 202 - 207
  • [6] Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis
    Marchand, V
    Baker, SS
    Stark, TJ
    Baker, RD
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 31 (03): : 264 - 269
  • [7] CHOLECALCIFEROL SUPPLEMENTATION AND INFLAMMATION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL
    Seibert, Eric
    Ulrich, Christof
    Trojanowicz, Bogusz
    Lehmann, Ulrike
    Dierkes, Jutta
    Stangl, Gabriele I.
    Girndt, Matthias
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [8] Zinc supplementation in prediabetes: A randomized double-blind placebo-controlled clinical trial
    Ranasinghe, Priyanga
    Wathurapatha, Wasundara S.
    Galappatthy, Priyadarshani
    Katulanda, Prasad
    Jayawardena, Ranil
    Constantine, Godwin R.
    [J]. JOURNAL OF DIABETES, 2018, 10 (05) : 386 - 397
  • [9] A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis
    Epifanio, Matias
    Marostica, Paulo C.
    Mattiello, Rita
    Feix, Larissa
    Nejedlo, Regina
    Fischer, Gilberto B.
    Stein, Renato T.
    [J]. JORNAL DE PEDIATRIA, 2012, 88 (02) : 155 - 160
  • [10] Randomized, double-blind, placebo-controlled crossover trial of Famotidine in patients with functional dyspepsia
    Kato, Mototsugu
    Yoshida, Takeshi
    Hata, Tamotsu
    Ono, Yuji
    Ono, Shouko
    Nakagawa, Manabu
    Nakagawa, Souichi
    Shimizu, Yuichi
    Asaka, Masahiro
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A158 - A158